We are international

Novel anti-myeloma therapy by targeting molecular signaling regulated by galectin family proteins
Junya Kuroda, MD, PhD
Division of Hematology and Oncology
Kyoto Prefectural University
Kyoto, Japan
Because myeloma cells acquire the chemo-resistant phenotype not only by cell intrinsic molecular abnormalities but also by the support of extracellular bone marrow (BM) components, it is essential to development new agents simultaneously targeted for those two divergent but mutually interacting, abnormal molecular signaling networks for myelomagenesis. To this purpose, Dr. Kuroda and colleagues are currently investigating the molecular signaling modulation which is specifically responsible for chemo-resistance of myeloma cells in tumor microenvironment model consisted of BM stromal cells, cytokines, and extracellular matrix. Preliminary data suggest that several members of galectins, a family of animal lectins that show affinity for b-galactosides (such as galectin-3 or galectin9), play important roles for myeloma cell survival, the resistance to cellular insults, cell adhesion, or deregulated cell proliferation in BM microenvironment.
 related articles
Bone marrow microenvironment and multiple myeloma chemotherapy optimization
Characterization and preclinical evaluation of NKT cells in multiple myeloma
Development of the antihelmintic flubendazole as a novel therapeutic agent for the treatment of multiple myeloma
Mesenchymal cell cytotherapy for multiple myeloma
MMSET and epigenetic control in t(4;14) myelomas
Reolysin: a novel reovirus-based therapy for multiple myeloma